Galena Biopharma Inc (GALE) was Downgraded by Raymond James to ” Mkt Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Raymond James advised their investors in a research report released on Jun 29, 2016.
On the company’s financial health, Galena Biopharma Inc reported $-0.07 EPS for the quarter, based on the information available during the earnings call on May 10, 2016. Analyst had a consensus estimate of $-0.07.During the same quarter in the previous year, the company posted $-0.08 EPS.
Galena Biopharma Inc closed down -0.09 points or -4.29% at $2.01 with 31,13,851 shares getting traded on Monday. Post opening the session at $2.1, the shares hit an intraday low of $1.97 and an intraday high of $2.13 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jun 7, 2016, Ryan Dunlap (Former Chief Financial Officer) sold 126,875 shares at $2.18 per share price.
Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.